# US 2025/0146089 A1 · Aberrant viral rna detection using cas13

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146089 A1
- Document ID: US20250146089A1
- Status: Published application
- Kind: A1
- Application number: 18/936,289
- Filed: 2024-11-04
- Published: 2025-05-08
- Earliest claimed: 2023-11-03
- Assignees: The Trustees of Princeton University
- Applicants: The Trustees of Princeton University
- Inventors: Caitlin Lamb; Arend Jan Wouter te Velthuis; Cameron Myhrvold
- Web page: https://patentgrep.com/patent/US20250146089A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed is a method for quantitative detection of a small, aberrant viral nucleic acid. The method includes combining a detection mixture with a sample, and allowing a reaction with the test mixture to begin. The sample includes an RNA sample. The detection mixture includes a Cas13 enzyme, a reporter, a sequence-specific CRISPR RNA (crRNA), and a buffer. The method includes determining a quantitative value representative of the reporter in the test mixture, where the quantitative value is a measure of an amount of target RNA present in the RNA sample.

## Claims

### Claim 1

A composition of matter, comprising:
a Cas13 enzyme;
a reporter;
a sequence-specific CRISPR RNA (crRNA); and
a buffer.

### Claim 2 (depends on 1)

The composition of matter of claim 1, wherein the Cas13 enzyme is LbuCas13a or LwaCas13a.

### Claim 3 (depends on 1)

The composition of matter of claim 1, wherein the Cas13 enzyme is a Cas13 enzyme other than LbuCas13a or LwaCas13a.

### Claim 4 (depends on 1)

The composition of matter of claim 1, wherein the reporter is a quenched fluorescent reporter or an affinity-based reporter.

### Claim 5 (depends on 1)

The composition of matter of claim 1, wherein the sequence-specific crRNA is configured to target a junction sequence formed upon aberrant viral RNA production.

### Claim 6 (depends on 5)

The composition of matter of claim 5, wherein the aberrant viral RNA is mini viral RNA (mvRNA).

### Claim 7 (depends on 1)

The composition of matter of claim 1, further comprising sample RNA.

### Claim 8

A method for quantitative detection of a small, aberrant viral nucleic acid, comprising:
forming a test mixture by combining a detection mixture with a sample, the sample comprising an RNA sample, the detection mixture comprising:
a Cas13 enzyme;
a reporter;
a sequence-specific CRISPR RNA (crRNA); and
a buffer;
allowing a reaction within the test mixture to begin; and
determining a quantitative value representative of the reporter in the test mixture, where the quantitative value is a measure of an amount of target RNA present in the RNA sample.

### Claim 9 (depends on 8)

The method of claim 8, wherein the reporter is a fluorescent reporter, a lateral flow reporter, a colorimetric reporter, or a luminescent reporter.

### Claim 10 (depends on 8)

The method of claim 8, wherein the value is a fluorescence or lateral flow readout.

### Claim 11 (depends on 8)

The method of claim 8, wherein the method is free of an amplification step.

### Claim 12 (depends on 8)

The method of claim 8, further comprising pre-amplification of the RNA sample.

### Claim 13 (depends on 8)

The method of claim 8, further comprising RNA fractionation.

### Claim 14 (depends on 8)

The method of claim 8, wherein the small, aberrant viral nucleic acid comprises synthetic RNA.

### Claim 15 (depends on 8)

The method of claim 8, wherein the small, aberrant viral nucleic acid comprises RNA produced by a virus.

### Claim 16 (depends on 15)

The method of claim 15, wherein the virus is a coronavirus, an arenavirus, a hantavirus, a paramyxovirus, an Ebola virus, a picornavirus, or a flavivirus.

### Claim 17 (depends on 8)

The method of claim 8, wherein the sample includes an antiviral, and the method further includes monitoring an infection status by repeating the forming, allowing, and determining steps and tracking the quantitative value over time.

### Claim 18 (depends on 1)

A detection system, comprising:
a detection mixture container, where a composition of matter of claim 1 is disposed within the detection mixture container; and
a detector configured to detect fluorescence of the composition of matter of claim 1.

### Claim 19 (depends on 1)

A detection kit, comprising:
a sample container; and
a detection mixture container, where a composition of matter of claim 1 is disposed within the detection mixture container.
